Q BioMed Inc (OTCMKTS:QBIO) Brings Nuclear Medicine Industry Expert To Commercialization Team

Q BioMed Inc (OTCMKTS:QBIO) reported that Christopher Manuele will join commercialization team of the Strontium 89 Chloride. Manuele is a results-driven, innovative executive with 35 years of comprehensive U.S. and global knowledge in nuclear medicine and medical isotope manufacturing.

The highlights

A long-time expert of GE Healthcare and Amersham Health, he has introduced core offerings; expanded products globally; led the construction, design and FDA-approval of two new manufacturing facilities in the U.S. and held responsibility for numerous full-GMP radiopharmaceutical production sites across the United States and Europe.

Prior to 2008, Mr. Manuele was associated with GE Healthcare in different roles. He has remarkable track record of operational excellence, incessant profitability improvement, and execution of top quality systems.

Q Biomed reported that Manuele joins the company’s VP of Product Development in directing the launch and advancement of the Strontium 89 offering. Mr. Laskow-Pooley possess experience of more than 40 years in different aspects of the discovery, commercialization and development of pharmaceutical products, devices and diagnostics.

He is an industry expert and has a notable career working for different pharmaceutical and life sciences firms. David has held executive officer, director and general management roles in both major and small multinational firms including GSK, Amersham plc, Abbott, OSI, Bilcare, Life technologies and Surface Therapeutics. Together with the team of technology associate BioNucleonics, Q Biomed has an experienced and capable team to support the launch and growth of this offering.

Following IV injection, soluble strontium compounds work like calcium analogs, dissipating rapidly from the blood and localizing in bone mineral. Acceptance of strontium by bone happens preferentially in areas of active osteogenesis; hence primary bone tumors and sites of metastatic involvement can accumulate considerably higher concentrations of strontium compared to surrounding normal bone. Strontium-89 stays in metastatic bone lesions for a longer period compared to normal bone, where turnover is nearly 14 days. In people with extensive skeletal metastases, more than 50% of the injected dose stays in the bones.